Alzamend Neuro
ALZN
20 hedge funds and large institutions have $2.7M invested in Alzamend Neuro in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
240% more call options, than puts
Call options by funds: $146K | Put options by funds: $43K
0% more funds holding
Funds holding: 20 → 20 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
33% less capital invested
Capital invested by funds: $4.01M → $2.7M (-$1.31M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$97.2K |
| 2 |
Renaissance Technologies
New York
|
+$62.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$58.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$24.6K |
| 5 |
KCIA
Kingsbury Capital Investment Advisors
Wilmette,
Illinois
|
+$13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$154K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$97K |
| 3 |
Millennium Management
New York
|
-$89.4K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$47K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$31.1K |
ALZN Hedge Fund Activity: Q2 2022 in Review
20 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q2 2022, worth a combined $2.7M — down 33% from $4.01M a quarter earlier.
Fund positioning in ALZN was balanced in Q2 2022: 6 funds opened new positions, 6 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $97.2K. The largest seller was Marshall Wace, exiting entirely with an estimated $154K sold.
- 20 institutional investors held Alzamend Neuro (ALZN) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $2.7M of Alzamend Neuro stock for Q2 2022, down 33% quarter-over-quarter.
- 6 funds opened new Alzamend Neuro positions in Q2 2022 and 6 closed out, a net change of 0 holders.
- The largest Alzamend Neuro buyer in Q2 2022 was Citadel Advisors, an estimated $97.2K added.
- The largest Alzamend Neuro seller in Q2 2022 was Marshall Wace, an estimated $154K sold.
Based on aggregated 13F filings for Q2 2022.